# Capecitabine and Oxaliplatin in Treating Patients With Locally Advanced, Unresectable, or Metastatic Stomach Cancer

> **NCT00354224** · PHASE2 · TERMINATED · sponsor: **Medical University of South Carolina** · enrollment: 10 (actual)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** capecitabine
- **DRUG:** oxaliplatin

## Key facts

- **NCT ID:** NCT00354224
- **Lead sponsor:** Medical University of South Carolina
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-01
- **Primary completion:** 2008-08
- **Final completion:** 2008-08
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** due to low accrual
- **Last updated:** 2018-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00354224

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00354224, "Capecitabine and Oxaliplatin in Treating Patients With Locally Advanced, Unresectable, or Metastatic Stomach Cancer". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT00354224. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*